Overview
- Editors:
-
-
W. J. Cunliffe
-
A. J. Miller
Access this book
Other ways to access
Table of contents (38 chapters)
-
Special Examinations with the Retinoids
-
-
- S. Gutschmidt, D. Tsambaos
Pages 165-177
-
Retinoids and Neoplasia
-
Front Matter
Pages 179-179
-
- G. Mathé, G. Santelli, J. Gouveia, G. Lemaigre, J. L. Misset, F. Gros et al.
Pages 181-186
-
-
-
Isotretinoin — Clinical and Laboratory
-
Front Matter
Pages 201-201
-
- D. H. Jones, W. J. Cunliffe, K. King, A. J. Miller
Pages 203-213
-
-
-
Isotretinoin — Duration of Remission of Acne
-
Front Matter
Pages 229-229
-
- H. Wokalek, R. Hennes, H. Schell, H. J. Vogt
Pages 231-239
-
- D. H. Jones, W. J. Cunliffe
Pages 241-251
-
Isotretinoin — Mechanism of Action
-
Front Matter
Pages 253-253
-
- W. J. Cunliffe, D. H. Jones, K. T. Holland, S. Millard, H. Al-Baghdadi
Pages 255-266
-
- J. R. Marsden, S. Shuster, F. Lyons
Pages 267-275
-
- M. Orme, D. J. Back, W. J. Cunliffe, D. H. Jones, W. L. Allen, J. Tjia
Pages 277-283
-
Comparisons of Isotretinoin with other Drugs in the Treatment of Severe Acne
-
Front Matter
Pages 285-285
-
- R. Greenwood, D. H. Jones, L. Brummitt
Pages 287-292
-
- D. H. Jones, W. J. Cunliffe, A. Löffler
Pages 293-301
About this book
The impact of the retinoids in clinical practice has primarily been in dermatology. When Dr Werner Bollag began his basic research and screening programme in the early 1960's, the expectation was that the retinoids would have a major impact on oncology. However, the laboratory and clinical experiences of Bollag and his colleagues in Switzerland, Stuttgen and Orfanos in Germany, led to publications on both etretinates (Tigason) and isotretinoin (Roaccutane) in the years between 1972 and 1976 in the field of dermatology. In fact the first symposium on retinoid research held in Berlin in 1981 was almost entirely dermatological. A year later a retinoid workshop in Iowa was designed to provide a forum for dermatolog ists from the USA involved in specific protocols investigating oral retinoids. In the UK, research into the retinoids began rather later than in Continental Europe or in the USA, although Tigason was first marketed here. It was felt in late 1982 that as many dermatologists had relatively little experience with these compounds it would be appropriate to hold an International Symposium on retinoid therapy in the UK. Thus on 16-18 May 1983 in London, 37 speakers from 11 countries addressed an audience of 300, aminly UK, dermatologists. The scientific organizing committee consisted of but two persons Dr William Cunliffe of Leeds General Infirmary, representing the European Society of Dermatolo gical Research, and myself from Roche Clinical Research. The Symposium was held under the auspices of the ESDR and of Roche Products Limited.